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ABSTRACT The virus family Flaviviridae encompasses several viruses, including
(re)emerging viruses which cause widespread morbidity and mortality throughout the
world. Members of this virus family are positive-strand RNA viruses and replicate their
genome in close association with reorganized intracellular host cell membrane compart-
ments. This evolutionarily conserved strategy facilitates efﬁcient viral genome replication
and contributes to evasion from host cell cytosolic defense mechanisms. We have previ-
ously described the identiﬁcation of a small-compound inhibitor, K22, which exerts a po-
tent antiviral activity against a broad range of coronaviruses by targeting membrane-
bound viral RNA replication. To analyze the antiviral spectrum of this inhibitor, we
assessed the inhibitory potential of K22 against several members of the Flaviviridae fam-
ily, including the reemerging Zika virus (ZIKV). We show that ZIKV is strongly affected by
K22. Time-of-addition experiments revealed that K22 acts during a postentry phase of
the ZIKV life cycle, and combination regimens of K22 together with ribavirin (RBV) or in-
terferon alpha (IFN-) further increased the extent of viral inhibition. Ultrastructural elec-
tron microscopy studies revealed severe alterations of ZIKV-induced intracellular replica-
tion compartments upon infection of K22-treated cells. Importantly, the antiviral activity
of K22 was demonstrated against several other members of the Flaviviridae family. It is
tempting to speculate that K22 exerts its broad antiviral activity against several positive-
strand RNA viruses via a similar mechanism and thereby represents an attractive candi-
date for development as a panviral inhibitor.
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Members of the family Flaviviridae are of major human health concern, and inseveral cases, the development of effective options for the prevention and
treatment of infections caused by these viruses is urgently awaited. The Flaviviridae
family comprises a wide variety of enveloped viruses possessing an RNA genome of
positive polarity, and it is subdivided into four genera: Hepacivirus, Flavivirus, Pegivirus,
and Pestivirus (1). While several new hepaciviruses were recently discovered in a variety
of species (2), the most prominent member, hepatitis C virus (HCV), is responsible for
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chronic infection in 71 million individuals worldwide, which are at risk of developing
liver cirrhosis and hepatocellular carcinoma (3). The genus Flavivirus encompasses 53
species and comprises a number of vector-borne, zoonotic agents responsible for acute
and self-limiting diseases, which can, in some cases, lead to severe symptoms (vascular
leakage, hemorrhage, encephalitis, meningitis) (4). As has been observed for Zika virus
(ZIKV), which has recently spread throughout South and Central America and the
Caribbean (5), several ﬂaviviruses are considered emerging or reemerging pathogens
and can rapidly become endemic, thereby leading to serious short- or long-term health
consequences (6). Hepaciviruses and ﬂaviviruses are therefore a major human health
concern. The newly proposed genus Pegivirus as well as the genus Pestivirus mainly
comprises virus species of veterinary relevance that cause gastrointestinal, respiratory,
and reproductive diseases in animals, which are associated with major economic losses
(7–9).
With the exception of HCV, intervention strategies against members of the family
Flaviviridae are limited. This emphasizes the need for the development of effective and
reliable drugs and vaccines, especially in the context of newly emerging or reemerging
viral infections.
Members of the Flaviviridae family share a highly similar genome organization and
replication strategy. Following attachment to the surface of the host cell and binding
of the cellular entry receptor, viral particles are internalized via the endocytic route and
incoming genomes are released into the cytosol. A single open reading frame (ORF)
encodes both structural proteins composing the viral particles (capsid/core, prM, and
envelope glycoproteins) (10) and nonstructural proteins primarily forming the viral
replicase complex that ensures polyprotein processing, membrane reorganization, and
RNA synthesis functions. Upon translation, the viral replicase is inserted in endoplasmic
reticulum membranes, where it orchestrates the establishment of replication organ-
elles. These organelles provide privileged, membrane-protected sites with which viral
RNA synthesis is closely associated (11). Given that virus-induced membrane remodel-
ing is a conserved mechanism among virtually all positive-sense RNA viruses, it repre-
sents an attractive target for the development of panviral inhibitors effective against a
wide range of viruses.
Recently, a screening which aimed at identifying anti-human coronavirus 229E
(HCoV-229E) compounds resulted in the identiﬁcation of a potent inhibitor, K22, which
efﬁciently abolished HCoV-229E plaque formation (12). The compound has been shown
to act on early postentry stages of coronavirus replication and to target membrane-
bound viral RNA synthesis. Moreover, K22 strongly prevented the formation of typical
HCoV-229E-induced perinuclear double membrane vesicle (DMV) clusters. A study by
Lundin et al. further extended the initial ﬁnding of the mechanism by which K22
inhibits HCoV-229E replication and demonstrated a potent pancoronavirus antiviral
activity of K22 (12). Indeed, K22 inhibited a broad range of coronaviruses from several
phylogenetic lineages (alpha-, beta-, and gammacoronaviruses), including murine hep-
atitis virus (MHV), type I feline coronavirus (FCoV), and avian infectious bronchitis virus
(IBV), as well as the highly pathogenic human severe acute respiratory syndrome-
associated coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus
(MERS-CoV) (12). Furthermore, it was recently reported that K22 impairs the replication
of not only viruses in the Coronavirinae subfamily but also members of the Torovirinae
subfamily, such as white beam virus (WBV; genus Baﬁnivirus) and equine torovirus
(EToV; genus Torovirus), as well as porcine reproductive and respiratory syndrome virus
(PRRSV) and equine arteritis virus (EAV), which are representative arteriviruses (13).
Here we evaluated the potential of K22 to inhibit the replication of members of the
family Flaviviridae. We show that K22 efﬁciently impairs the replication of ZIKV, yellow
fever virus (YFV), Japanese encephalitis virus (JEV), and West Nile virus (WNV), as well
as, to a certain extent, Usutu virus (USUV), Wesselsbron virus (WESSV), HCV, and bovine
viral diarrhea virus (BVDV). Collectively, our study indicates a broad antiviral activity of
K22 against a wide range of Nidoviridae and Flaviviridae lineages and suggests that
interfering with conserved mechanisms of membrane rearrangements and the biogen-
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esis of replication organelles could represent a novel target for the development of
antiviral drugs to combat positive-sense RNA virus infections.
RESULTS
K22 inhibits ZIKV in a dose-dependent manner. Given our previous ﬁndings that
the small-compound inhibitor K22 may interfere with conserved features of virus-
induced membrane remodeling, we hypothesized that K22 might, in addition to
coronaviruses and arteriviruses, impair the replication of viruses belonging to the family
of Flaviviridae, such as ZIKV. To test this hypothesis, K22-treated cells were infected with
ZIKV and virus replication was assessed at 24 and 48 h postinfection (p.i.) by measuring
the intracellular levels of E proteins by ﬂow cytometry. The percentage of cells harbor-
ing replicating virus, reﬂected by E protein expression, was signiﬁcantly decreased, in
a dose-dependent manner, upon treatment of cells with K22 at 48 h p.i. (Fig. 1a).
Titration of the viral supernatant conﬁrmed the signiﬁcant inhibition of ZIKV infectivity
upon K22 treatment at both time points, i.e., at 24 and 48 h p.i., with 50% inhibitory
concentrations (IC50s) of 2.5 M and 2.1 M, respectively (Table 1). Indeed, 5 or 10 M
K22 was sufﬁcient to reduce the viral titers by 1 to 2 orders of magnitude. Higher
concentrations of K22 reduced viral titers by up to 4 orders of magnitude (Fig. 1b). Flow
cytometric analysis revealed no cytotoxic effect of K22 at the concentrations indicated
in Fig. 1c, as determined upon application of a Fixable Aqua dead cell stain kit. These
results were conﬁrmed upon assessment of cytotoxicity using a commercially available
kit (Fig. 1d). However, similar to what has been previously reported (12), K22 concen-
trations of 30 M mildly affected cell proliferation (Fig. 1d; see also Fig. S1 in the
supplemental material), suggesting that the observed antiviral effects at concentrations
of 30 M were slightly overestimated. In order to determine which step of the viral
replication cycle is affected by K22, we performed time-of-addition experiments. To
exclude the possibility of direct effects of K22 on viral particles, e.g., disruption of the
viral envelope or interference with virion stability, we preincubated ZIKV with increas-
ing K22 concentrations and subsequently assessed the remaining infectivity by titra-
tion. We showed that preincubation of K22 does not affect ZIKV infectivity (Fig. 1e).
Next, K22 was added to the cells at different times pre- or postinfection, and the effects
on viral replication and infectivity were determined by titration of the viral supernatant.
Interestingly, K22 also displayed antiviral activity when added at several hours postin-
fection, suggesting an effect on postentry stages of the ZIKV life cycle (Fig. 1f).
Collectively, our data reveal that K22 signiﬁcantly inhibits ZIKV in a dose-dependent
manner, likely by impairing a critical postentry step in the ZIKV life cycle.
K22 inhibits several members of the family Flaviviridae. We next assessed
whether K22 displays a broad antiviral effect on the replication of other Flaviviridae
members. To this end, we tested the K22 sensitivity of different ﬂaviviruses, including
JEV, YFV, WNV, USUV, and WESSV, as well as the hepacivirus HCV and the two
representative pestivirus BVDV biotypes (cytopathogenic [Cp] and noncytopathogenic
[Ncp]) of a bovine viral diarrhea pestivirus pair. Cells were treated with increasing
concentrations of K22 and infected. Intracellular levels of the ﬂavivirus E protein, as a
marker of viral replication, were assessed by ﬂow cytometry. Moreover, viral titers in the
supernatant were determined by 50% tissue culture infective dose (TCID50) titration. This
showed that both JEV and YFV replication (Fig. 2a and c) and infectivity (Fig. 2b and d) were
reduced by K22 concentrations starting from 5 M K22 in a dose-dependent manner,
with IC50s being between 0.5 and 4.4 M (Table 1). WNV (Fig. 2e and f) replication as
well as infectivity was signiﬁcantly reduced at K22 concentrations of10 M, with IC50s
being 2.8 M at 24 h and 8.4 M at 48 h (Table 1). Slightly higher K22 concentrations
(20 M) were necessary to signiﬁcantly inhibit USUV (Fig. 2g and h) and WESSV (Fig.
2i and j), with IC50s being between 5.9 and 10 M (Table 1). To analyze the antiviral
effect of K22 on the hepacivirus HCV, a luciferase-encoding reporter virus was used, and
virus-mediated intracellular luciferase expression was measured as a marker for viral
replication. Furthermore, to rule out the possibility that K22 has an impact on the
luciferase reporter activity, a nonreporter HCV construct (HCV Jc1) was employed and
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quantitative real-time PCR (qRT-PCR) analysis of HCV RNA levels was performed (Fig.
S2). In addition, the viral supernatant from infected, K22-treated cells was harvested
and used to inoculate naive target cells before the latter were lysed and luciferase
reporter activity was determined (infectivity). Similar to the ﬁndings for WNV and USUV,
FIG 1 K22 inhibits ZIKV replication and acts at a postentry stage. Vero cells were treated for 4 h with different concentrations of K22. Cells were infected with
ZIKV (MOI  0.1 TCID50/cell) for 1 h before the medium was removed and medium containing the different concentrations of K22 was added. (a) At 24 h and
48 h p.i., cells were harvested and E protein expression was analyzed by ﬂow cytometry. (b) Viral infectivity was determined by harvesting the supernatant of
cells and performing a TCID50 assay on Vero cells. (c) Cells treated with the compound were stained with a live/dead cell marker, and the MFI was determined
by ﬂow cytometric analyses. Shaded bars represent the positive control of dead cells. (d) Commercially available cell toxicity assays (cytotoxicity; CytoTox 96
nonradioactive cytotoxicity assay; Promega) as well as viability assays (proliferation; MultiTox-Fluor multiplex cytotoxicity assay; Promega) were performed to
determine the cytotoxic effect of K22 on Vero B4 cells at 24 h posttreatment. (e) To evaluate the direct effect of K22 on viral stability, ZIKV in DMEM was
incubated for 2 h at room temperature with the different K22 concentrations, and the viral titer was determined as the number of TCID50 per milliliter. (f)
Time-of-addition assays were performed to analyze the effect of K22 on the early virus-cell interaction. K22 at various concentrations was added at speciﬁc time
points relative to the time of infection with ZIKV, and the cell culture supernatants were collected at 24 h p.i. for measurement of virus release. The results
represent the mean (bar) SD (n 2 or 3). Dotted lines indicate the limit of detection. n.d., not detected. P values were determined by 2-way ANOVA, followed
by Dunnett’s multiple-comparison test. ****, P  0.0001; ***, P  0.001; **, P  0.01; *, P  0.05; n.s., not signiﬁcant.
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K22 concentrations of 20 M led to a signiﬁcant reduction of viral replication as well
as infectivity (Fig. 3a and b and S2). However, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) cell proliferation assays indicated that the cells
used for infection were affected by K22 concentrations of 20 M (Fig. 3c). Neverthe-
less, a 50% cytotoxic concentration (CC50) value (21.3 M) 3-fold higher than the IC50
(7.0 M) (Table 2) revealed an antiviral effect of K22 on HCV which could be distin-
guished from the effect on cell viability. Nevertheless, careful interpretation of the data
is still required, as the antiviral effect displayed by K22 may be overestimated in the
context of HCV infections. Two biotypes of BVDV strain Suwa were tested for their
susceptibility to K22 treatment. Viral RNA levels were determined by qRT-PCR as a
correlate for viral replication, and viral titers in the supernatant were assessed by
titration. Similar to the ﬁndings for HCV, K22 concentrations of 20 M and 40 M
were necessary to signiﬁcantly reduce the viral replication of Cp BVDV strain Suwa
(BVDV SuwaCp) (Fig. 3e) and Ncp BVDV strain Suwa (BVDV SuwaNcp) (Fig. 3g), respec-
tively. Viral titers were signiﬁcantly reduced upon treatment with 20 to 50 M K22 for
BVDV SuwaCp (Fig. 3f), with the IC50 being 14.2 M (Table 2), whereas at least 40 M
K22 was necessary to signiﬁcantly reduce the infectivity of BVDV SuwaNcp, with the
IC50 being 21.4 M (Fig. 3h; Table 2). Of note, even though no cellular toxicity resulting
from K22 incubations at the concentrations indicated above could be measured, cell
proliferation was affected at K22 concentrations of 30 M, as described before (Fig.
3d; Table 2). Collectively, our data show that K22 inhibits a broad range of Flaviviridae
members, including JEV, YFV, WNV, USUV, WESSV, and, to a limited extent, HCV and
BVDV.
Combination treatment regimens enhance the antiviral activity of K22. Treat-
ment options against members of the family Flaviviridae remain limited, despite the
recent success regarding the treatment of HCV infections with the development of
direct-acting antivirals (DAA) (14). The recent ZIKV epidemic further underscored the
importance of effective viral inhibitors, which can be applicable to rapidly control
outbreaks of (re)emerging viruses. Ribavirin (RBV) and interferon alpha (IFN-) have
been employed for their well-documented antiviral activity against several RNA viruses
(15). We therefore evaluated the antiviral potential of a combination regimen of K22
together with RBV or IFN- against ZIKV. To this end, cells were treated either with K22,
RBV, or IFN- alone or with a two drug-combination and subsequently infected for 24 h
before the viral titers in the supernatant were determined by a TCID50 assay. A single
treatment with 5 or 10 M K22 was sufﬁcient to signiﬁcantly reduce the viral titers (Fig.
4a). A single treatment with 10 g/ml RBV moderately reduced the viral titers, whereas
increased concentrations of 100 g/ml and 1,000 g/ml correlated with signiﬁcantly
reduced viral titers in the supernatant (Fig. 4b). However, high RBV concentrations (100
g/ml to 1,000 g/ml) also impacted cell viability (Fig. S3b). IFN- was effective against
ZIKV at doses of10 IU (Fig. 4c), with no effect on cell viability (Fig. S3c). A combination
treatment of K22 with either 0.1 or 1 g/ml RBV did not improve the antiviral effect of
K22; however, the addition of at least 10 g/ml RBV in combination with low K22
concentrations (5 to 10 M) increased the overall antiviral effect (Fig. 4d and g).
Furthermore, a combination of 10 or 20 M K22 together with 100 g/ml RBV reduced
TABLE 1 IC50 values and selectivity indexes for the effect of K22 treatment on ﬂavivirus
infectivity
Virus
24 h p.i. 48 h p.i.
IC50 (M) SIa IC50 (M) SI
ZIKV 2.5 35.6 2.1 39.9
JEV 0.5 193.9 4.4 19.1
YFV 3.7 24.3 2.3 36.7
WNV 2.8 32.3 8.4 10.0
USUV 9.0 10.0 10.0 8.4
WESSV 5.9 15.2 6.8 12.5
aSI, selectivity index.
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FIG 2 K22 inhibits the replication and infectivity of several members of the Flavivirus genus. Vero cells were treated for
4 h with different concentrations of K22. Cells were infected with JEV (a, b), YFV (c, d), WNV (e, f), USUV (g, h), and WESSV
(Continued on next page)
García-Nicolás et al. Antimicrobial Agents and Chemotherapy
November 2018 Volume 62 Issue 11 e01206-18 aac.asm.org 6
 o
n
 N
ovem
ber 21, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
the viral titers by 4 to 5 orders of magnitude compared to those for the untreated
control (Fig. 4d and g). Similarly, combination treatment with doses of 10 IU IFN-
together with K22 potentiated the antiviral effect (Fig. 4e and g). In particular, 5 to 10
M K22 combined with10 IU IFN- resulted in viral titers reduced by at least 3 orders
of magnitude without any further impact on cell proliferation (Fig. 4e and S3e).
Combination treatments with RBV and IFN- at doses of 100 IU IFN- and 100
g/ml RBV increased the antiviral effectiveness against ZIKV compared to that of either
single treatment (Fig. 4f). Analysis of the drug combination K22 and RBV at concen-
trations in the range of the concentrations of each drug that caused only partial
inhibition of replication pointed to an additive antiviral effect of the two compounds,
indicated by combination indexes (CI) of about 1 (Fig. S4). For K22 combined with
IFN-, a slight synergism was observed for 10 IU IFN- (6.73  106 M) and K22
concentrations between 10 and 30 M, indicated by a CI of 1. In conclusion, K22
treatments in combination with RBV and IFN- allow the use of reduced K22 concen-
trations for a level of ZIKV replication impairment similar to that achieved with higher
concentrations of K22, RBV, or IFN- alone while protecting the cells from potential
K22- or RBV-induced cytotoxicity when used at high concentrations.
K22 interferes with membrane reorganization during ZIKV infection. We have
previously reported that K22 prevents the formation of typical HCoV-229E-induced
perinuclear DMV clusters, suggesting that K22 interferes with coronavirus replication by
impairing membrane-bound replication compartment biogenesis (12). We therefore
assessed whether the antiviral effect of K22 observed against Flaviviridae, speciﬁcally,
against ZIKV, correlates with the impaired establishment of ZIKV-induced replication
organelles. To this end, ZIKV-infected cells were ﬁxed at 48 h p.i. and assessed by
ﬂuorescence microscopy. Immunoﬂuorescence analysis revealed that the vast majority
of cells were infected, as both viral E protein and double-stranded RNA (dsRNA) were
efﬁciently detected in most cells (Fig. 5, left). In concordance with previous results (Fig.
1), both markers of viral infection were severely reduced upon K22 treatment (30 M),
thereby conﬁrming the potent antiviral effect of K22 on ZIKV infections (Fig. 5, right).
Additional immunoﬂuorescence analyses with selected ﬂaviviruses (JEV and WNV)
further conﬁrmed the antiviral activity of the compound (Fig. S5). Furthermore, ultra-
structural ZIKV-induced membrane rearrangements were assessed by transmission
electron microscopy (TEM). Despite a vast majority of dimethyl sulfoxide (DMSO)-
treated cells being infected (Fig. 5), structures reminiscent of well-described ZIKV
membranous replication organelles were only occasionally observed in ZIKV-infected
cells (Fig. 6). Fixation methods and cell type-speciﬁc determinants likely account for the
morphological differences from previously reported ZIKV-induced membranous struc-
tures (16). Accordingly, it was also reported that certain replication-associated struc-
tures were absent in ZIKV-infected human neural progenitor cells and that vesicular
structures were markedly smaller than the ones observed in ZIKV-infected Huh-7 cells
(16). In sharp contrast, we repeatedly observed a striking accumulation of large vesicles
in the cytosol of ZIKV-infected cells treated with K22, while morphological changes of
cellular compartments (dilated vesicular structures) were only occasionally seen in
noninfected cells treated with K22 (Fig. 6). These vesicles were notably larger than
previously described ZIKV replication organelles (16), as vesicles of at least 500 nm in
diameter were frequently observed, and these are unlikely to represent conventional
ZIKV-induced replication organelles. Rather, they are suggestive of aberrant structures
that do not support ZIKV replication as a result of K22 treatment.
FIG 2 Legend (Continued)
(i, j) (MOI  0.1 TCID50/cell) for 1 h before the medium was removed and fresh medium containing the different
concentrations of K22 was added. At 24 h and 48 h postinfection, cells and supernatants were harvested. (a, c, e, g) Cells
were stained for anti-ﬂavivirus group antigen antibody, and the percentage of positive cells was determined by ﬂow
cytometric analysis; (b, d, f, h) viral infectivity was determined from the supernatants of infected cells by performing a
TCID50 assay on Vero cells. The results represent the mean (bar)  SD (n  3). The dashed lines indicate the limit of
detection. P values were determined by 2-way ANOVA followed by Dunnett’s multiple-comparison test. ****, P 0.0001;
***, P  0.001; **, P  0.01; *, P  0.05; n.s., not signiﬁcant.
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FIG 3 K22 inhibits the replication and infectivity of hepacivirus and pestivirus. Huh7-Lunet-N-hCD81-FLuc cells were
pretreated with K22 for 3 h before supernatant removal and infection with JcR-2a virus for 3 h at 37°C. After this, the
inoculum was removed and the compounds were added and left until the end of the experiment. (a) At 48 h p.i., the cells
were lysed and Renilla luciferase (replication) activity was measured. (b) Infectious supernatants were harvested and
transferred onto target Huh7-Lunet-N-hCD81-FLuc cells. Target cells were lysed at 72 h p.i., and Renilla luciferase activity
(infectivity) was determined. Data are depicted as relative light units (RLU). (c) The viability of Huh7-Lunet-N-hCD81-FLuc
cells after K22 treatment was determined upon MTT assay, and the data were normalized to those for untreated cells.
(Continued on next page)
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Taken together, we observed an alteration of the intracellular membrane organiza-
tion upon ZIKV infection in combination with K22 treatment associated with a strong
reduction of intracellular levels of dsRNA and E protein. Even though the precise
mechanism of action of K22 remains to be elucidated, interference with membrane
remodeling functions and membrane-bound RNA replication provides a plausible
explanation for the observed pan-antiviral effects.
DISCUSSION
Many members of the family Flaviviridae are important human and veterinary
pathogens. Especially, several members of the Flavivirus genus are considered
(re)emerging viruses, which are deﬁned as pathogens that have existed previously
or have newly appeared in a population and are increasing in incidence or
geographic range (17). Successful treatment of HCV infections has been achieved in
the last couple of years with the development of highly effective direct-acting antiviral
(DAA) therapies (18). Moreover, favipiravir, also known as T-705 or Avigan, is in use
against YFV and WNV infections (as well as infections caused by arenaviruses, bunya-
viruses, and alphaviruses) (19), and host-directed compounds, such as cyclophilin
inhibitors (20, 21) and -glucosidase inhibitors (22), have been evaluated in clinical
trials to control HCV and dengue virus (DENV) infections, respectively. Furthermore,
prophylactic options, such as vaccination, have been developed for YFV, JEV, and
tick-borne encephalitis virus (TBEV) (23), as well as for DENV, although the vaccine
against DENV suffers from limited efﬁcacy (24, 25). On the other hand, vaccines for
humans to combat HCV, WNV, and ZIKV are not available (26). Taken together, the
available panel of prophylactic and antiviral treatment options against ﬂavivirus infec-
tions in human and animals remains limited, thus emphasizing the need for the
development of effective and reliable drugs/vaccines.
Following a screening which aimed at identifying anti-HCoV-229E compounds, we
have described a potent small-compound inhibitor, K22, which efﬁciently inhibited
coronavirus replication and was recently shown to additionally inhibit a wide range of
virus species within the families Coronaviridae and Arteriviridae (12, 13). K22 has been
shown to act on early postentry stages of coronavirus replication and to target
membrane-bound RNA synthesis by interfering with the establishment of virus-induced
replicative structures. Importantly, HCoV-229E mutants that were able to replicate in
the presence of K22 were isolated following several virus passages on K22-treated cells.
These escape mutants contained amino acid substitutions in nonstructural protein 6
(nsp6; H121L, M159V) that were associated with K22 resistance. Coronavirus nsp6
FIG 3 Legend (Continued)
Depicted are the data normalized to those for untreated cells. (d) The viability of BT cells after K22 treatment was
determined using commercially available cell toxicity assays (cytotoxicity; CytoTox 96 nonradioactive cytotoxicity assay;
Promega) as well as viability assays (proliferation; MultiTox-Fluor multiplex cytotoxicity assay; Promega). Depicted are the
data normalized to those for the DMSO-treated cells. (e to h) BT cells were treated with K22 for 4 h before supernatant
removal and infection with BVDV SuwaCp (e, f) or BVDV SuwaNcp (g, h) for 1 h at 37°C before the medium was removed
and medium containing the different concentrations of K22 was added. (e, g) Cells were lysed at 48 h p.i., and intracellular
RNA was extracted. qRT-PCR was performed, and viral replication was calculated using the ΔΔCT method and is depicted
as the fold induction compared to that for DMSO-treated control cells. (f, h) Viral titers were determined by serial dilution
on BT cells at 4 days p.i. The results represent the mean (bar) SD (n 3). The dashed lines indicate the limit of detection.
P values were determined by 1-way ANOVA followed by Dunnett’s multiple-comparison test. ****, P  0.0001; ***, P 
0.001; **, P  0.01; *, P  0.05; n.s., not signiﬁcant.
TABLE 2 IC50 values, CC50 values, and selectivity indexes for the effect of K22 treatment
on hepacivirus and pestivirus replication and infectivity
Virus
IC50 (M) for:
SIa
CC50 (M) for:
Replication Infectivity Proliferation Cytotoxicity
HCV 7.0 2.2 9.7 21.3
BVDV SuwaCp 15.5 14.2 24.6 350 1,000
BVDV SuwaNcp 34.7 21.4 16.4 350 1,000
aSI, selectivity index.
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contains multiple membrane-spanning domains and is essential to membrane diver-
sion events leading to the biogenesis of replication organelles (27). These ﬁndings
thereby corroborate a critical step inhibited by K22 during membrane remodeling
events.
Given these ﬁndings, we speculated that K22 might offer potential as a panviral
inhibitor, considering that replication strategies are highly similar between members of
the family Flaviviridae and other positive-strand RNA viruses. Indeed, we show here that
several members of the Flaviviridae are efﬁciently inhibited by K22, with these viruses
including ZIKV, JEV, YFV, WNV, USUV, WESSV, and, to a limited extent, HCV and BVDV.
Moreover, combination treatment regimens with the approved broad-acting antivirals
RBV and IFN- supported the antiviral effect of K22 on ZIKV. This ﬁnding implies not
only that effective K22 concentrations can be substantially reduced but also that the
therapeutic window of K22 can be improved. Our results should also encourage efforts
to improve the antiviral activity of K22 by assessing further chemical modiﬁcations to
reduce possible cytotoxicity and the impact of K22 on cell proliferation and thereby
enhance the therapeutic range of K22.
FIG 4 Combination treatment regimens enhance the antiviral effect of K22 on ZIKV. Vero B4 cells were infected with ZIKV (MOI 0.1 TCID50/cell) for 1 h, before
the inoculum was discarded and the cells were washed with PBS. The compounds were added at various concentrations. (a) K22 single treatment; (B) RBV single
treatment; (c) IFN- single treatment; (d) K22-RBV combination treatment; (e) K22–IFN- combination treatment; (f) RBV–IFN- combination treatment. The cell
culture supernatants were collected at 24 h p.i., and viral titers were determined as the number of TCID50 per milliliter. The results represent the mean  SD
(n  3). The dashed lines indicate the limit of detection. P values were determined by 1-way ANOVA followed by Dunnett’s multiple-comparison test. ****,
P  0.0001; ***, P  0.001; **, P  0.01; n.s., not signiﬁcant. (g to i) Three-dimensional blots depicting the viral titers for each combination.
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Compartmentalization of the viral replication machinery within host-derived endo-
membrane structures is a conserved hallmark among positive-sense RNA viruses (11,
28, 29) and is hypothesized to provide optimized concentrations of macromolecules
and to coordinate the regulated succession of events required for efﬁcient viral
replication. Furthermore, compartmentalization protects viral replication intermediates,
such as dsRNA, from recognition by cytosolic pattern recognition receptors that elicit
the ﬁrst steps of a host innate immune response (30–32). Time-of-addition experiments
in the context of ZIKV revealed that K22 acts at a postentry stage, presumably during
the establishment of viral replication in the cytosol of the infected cell, reminiscent of
the suggested mode of action in the context of HCoV-229E inhibition (12). Subsequent
ultrastructural analyses of ZIKV-infected cells following K22 treatment revealed the
predominant appearance of aberrant vacuoles in the cytosol of infected cells associated
with the pronounced reduction of perinuclear dsRNA accumulation observed by ﬂuo-
rescence imaging. We therefore speculate that K22 interferes with the biogenesis of
replicative organelles by prematurely abrogating membrane diversion functions lead-
ing to functional replicative structures. However, whereas K22 completely prevented
FIG 5 K22 inhibits E protein and dsRNA accumulation in ZIKV-infected cells. Vero cells were pretreated with 30 M
K22 or DMSO for 4 h before infection with ZIKV (MOI 0.1 TCID50/cell). DMSO-treated and noninfected cells (Mock)
were included as controls. The inoculum was removed after 1 h, and the cells were washed with PBS. At 48 h p.i.,
the cells were ﬁxed and processed for immunoﬂuorescence analysis using antibodies directed against ﬂavivirus E
protein and dsRNA as markers of ZIKV replication. Cells were counterstained with phalloidin (actin) or DAPI (nuclei).
z-projections of multiple optical sections acquired with a Nikon confocal A1 microscope combined with an Eclipse
Ti inverted microscope are shown. Bars, 20 m.
K22 Inhibits Flaviviridae Antimicrobial Agents and Chemotherapy
November 2018 Volume 62 Issue 11 e01206-18 aac.asm.org 11
 o
n
 N
ovem
ber 21, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
the formation of coronavirus replicative organelles (12), K22 appeared to increase
membrane proliferation and the vesicle size of ZIKV-induced replication structures.
Whether this suggests either different mechanisms by which K22 interferes with the
formation of functional replication complexes or the action of the same mechanism
with a different outcome remains to be elucidated.
In conclusion, we describe the antiviral activity of a small-compound inhibitor, K22,
against several members of the family Flaviviridae, in addition to the previously
reported antiviral effect against members of the family Coronaviridae and other nido-
viruses. K22 therefore represents a potential panviral inhibitor and could complement
current intervention strategies against several (re)emerging viral diseases.
FIG 6 Ultrastructural analysis of the K22-mediated alteration of ZIKV replication compartment formation.
Vero B4 cells were pretreated with 30 M K22 for 2 h and infected with ZIKV (MOI  10 TCID50/cell) for
24 h. The inoculum was removed at 1 h p.i., and the cells were washed with PBS. DMSO-treated and
noninfected cells (mock) were included as controls. The cells were ﬁxed at 24 h p.i. and processed for
ultrastructural analyses by TEM of ultrathin sections 90 nm thick. Magniﬁcations of representative areas
indicated by squares in the left panels are shown on the right.
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MATERIALS AND METHODS
Cell culture and viral strains. The present work included several ﬂaviviruses: a low-passage-number
JEV Laos strain belonging to genotype 1 (G1; CNS769/Laos/2009; GenBank accession number
KC196115.1; kindly provided by R. Charrel, Aix-Marseille Université, Marseille, France), a low-passage-
number ZIKV clinical isolate (5 passages) of the Asian lineage obtained from a viremic patient in Puerto
Rico in 2015 (PR-2015; PRVABC59; GenBank accession number KX377337; obtained from Public Health
England [PHE]), WNV NY99 (GenBank accession number DQ211652.1) and the high-passage-number
African lineage USUV SAAR-1776 strain (GenBank accession number AY453412) (both WNV NY99 and
USUV SAAR-1776 were kindly provided by R. Hoop, Institute of Veterinary Bacteriology University of
Zürich, Zürich, Switzerland), WESSV strain SAH-177 99171-2 (GenBank accession number EU707555.1;
obtained from European Virus Archive goes global [EVAg]), and ﬁnally, the YFV 17D strain used in the
Stamaril vaccine (GenBank accession number X03700). The JEV, WNV, USUV, and YFV strains were
propagated in Vero cells (ATCC CCL81; American Type Culture Collection, VA, USA) in Glasgow minimum
essential medium (G-MEM-BHK-21; Gibco, Thermo Fisher Scientiﬁc, Reinach, Switzerland) supplemented
with 2% (vol/vol) fetal bovine serum (FBS; Biowest, Nuaillé, France) and cultured at 37°C in a 5% CO2
atmosphere. ZIKV and WESSV were was passaged in Aedes albopictus C6/36 cells cultured in G-MEM-
BHK-21 (Gibco) supplemented with 2% (vol/vol) FBS (Biochrom; Bioswisstec AG, Schaffhausen, Switzer-
land) at 28°C in 5% CO2. HCV JcR-2a stocks were obtained by electroporation of Huh-7.5 cells with in
vitro-transcribed HCV RNA, as previously described (33). JcR-2a is a full-length recombinant HCV genome
based on the Jc1 intragenotypic HCV chimera (34) and, further, encodes the Renilla luciferase reporter
gene (35). Huh7-Lunet-N-hCD81-FLuc cell lines were grown at 37°C with 5% CO2 in Dulbecco’s modiﬁed
Eagle’s medium (DMEM; Invitrogen, Thermo Fisher Scientiﬁc) supplemented with 2 mM L-glutamine,
nonessential amino acids (NEA), 100 U/ml of penicillin, 100 g/ml of streptomycin, and 10% (vol/vol) FBS.
For the Huh7-Lunet-N-hCD81-FLuc cell line, blasticidin was added to the culture medium at a concen-
tration of 5 g/ml. BVDV strains SuwaCp and SuwaNcp were isolated at the Institute of Virology and
Immunology (36) and passaged on embryonic bovine turbinate (BT) cells as described previously (37) in
Eagle minimal essential medium (Gibco) supplemented with 7% (vol/vol) FBS (PAA; PAA Laboratories, GE
Healthcare, Glattbrugg, Switzerland), 1% (vol/vol) GlutaMAX (Gibco), 1% (vol/vol) penicillin-streptomycin
(Biochrom), 0.5% (vol/vol) neomycin-bacitracin (Biochrom), and 1% (vol/vol) NEA (Biochrom).
Reagents. K22 (structural name, (Z)-N-{3-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-3-oxo-1-
phenylprop-1-en-2-yl} benzamide) was purchased from ChemDiv (catalog number 4295-0370; San Diego,
CA) and DMSO. RBV was purchased from Sigma-Aldrich (catalog number R9644; Buchs, Switzerland), and
recombinant human IFN-A/D (IFN-) was purchased from Sigma-Aldrich (catalog number I4401). Stock
solutions were prepared in H2O and stored according to the manufacturer’s recommendations.
Infection experiments. To test the effect of K22 on ﬂavivirus, hepacivirus, and pestivirus infection,
8  104 Vero cells were seeded in 12-well dishes (ﬂaviviruses), 5  104 Huh7-Lunet-N-hCD81-FLuc cells
were seeded in 12-well dishes (hepacivirus), or 1 104 BT cells were seeded in 96-well dishes (pestivirus).
At 1 day postseeding, cells were treated with different concentrations of K22 (diluted in DMSO at the
concentrations indicated below) for 3 to 4 h and preincubated in 5% CO2 at 37°C. Cells were infected with
different viruses at a multiplicity of infection (MOI) of 0.1 TCID50/cell for 1 h at 37°C. For HCV infection,
cells were infected with JcR-2a or HCV Jc1 for 3 h at 37°C. Afterwards, cells were washed with prewarmed
phosphate-buffered saline (PBS) solution, before cell culture medium supplemented with K22 or the
DMSO control at each concentration was added, and incubated at 37°C in a 5% CO2 atmosphere. At 24
h and/or 48 h postinfection (p.i.), supernatants and cells were collected for further analysis.
Flavivirus replication and infectivity. Flavivirus replication and the cytopathic effect (CPE) were
evaluated from collected cells. Cells in suspension were ﬁrst labeled with the Fixable Aqua dead cell stain
kit (Thermo Fisher Scientiﬁc, Waltham, MA, USA) for 30 min on ice, followed by washing with cold PBS.
Then, the suspended cells were ﬁxed with 4% (wt/vol) paraformaldehyde (PFA) for 10 min on ice and
thereafter washed and permeabilized with 0.3% (wt/vol) saponin in PBS supplemented with anti-
ﬂavivirus group antigen antibody 4G2 (catalog number HB-112; ATCC) for 15 min on ice. After washing,
anti-mouse IgG2a conjugated with Alexa Fluor 647 (Thermo Fisher Scientiﬁc) was added for 15 min, and
the cells were acquired on a FACSCanto II ﬂow cytometer (BD Biosciences, Allschwil, Switzerland). FlowJo
(v.9.1) software (TreeStar, Inc., Ashland, OR, USA) was used for analysis. Cell debris and doublets were
excluded by electronic gating in forward/side scatter plots. Cell culture supernatants were collected at
24 and 48 h p.i., and the ﬂavivirus titers in Vero cells were determined using the immunoperoxidase
monolayer assay (IPMA). For that, supernatants 10-fold diluted in cell culture medium supplemented
with 2% (vol/vol) FBS were incubated on Vero cells for 72 h at 37°C in a 5% CO2 atmosphere. At that
point, cells were ﬁxed in 4% (wt/vol) PFA for 10 min at room temperature, washed, and immunolabeled
with anti-ﬂavivirus group antigen antibody 4G2 diluted in 0.3% (wt/vol) saponin in PBS for 30 min at 37°C
and then washed and incubated for another 30 min at 37°C with goat anti-mouse IgG conjugated with
horseradish peroxidase (Dako), followed by incubation for 10 to 30 min at room temperature with
3-amino-9-ethylcarbazole (AEC) substrate (Sigma-Aldrich). Titers were calculated and expressed as the
number of TCID50 per milliliter using the Reed and Muench method (38).
Hepacivirus replication and infectivity. Cells were lysed at 48 h p.i. in 150 l passive lysis buffer
(Promega) per well for the assessment of the Renilla luciferase (viral replication) activities. The details of
the Renilla luciferase assay have been described elsewhere (39). For the determination of HCV Jc1
replication, infections were performed as described above, but with Jc1 virus and an MOI of 1 or 0.1
TCID50/cell. Cells were lysed at 24 h p.i. for RNA extraction using a NucleoSpin RNA kit (Macherey-Nagel,
Düren, Germany) according to the manufacturer’s instructions. qRT-PCR of HCV RNA was performed in
duplex with a GAPDH (glyceraldehyde-3-phosphate dehydrogenase) calibrator in a LightCycler 480
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instrument (Roche, Mannheim, Germany) as described previously (40) but with 45 cycles and the
following primers and probes: primer HCV S-147 (5=-TCTGCGGAACCGGTGAGTA-3=), primer HCV A-221
(5=-GGGCATAGAGTGGGTTTATCCA-3=), an HCV probe (5=-6FAM-AAAGGACCCAGTCTTCCCGGCAA-TMR
[where 6FAM is 6-carboxyﬂuorescein and TMR is 6-carboxytetramethylrhodamine]), primer GAPDH S
(5=-GAAGGTGAAGGTCGGAGTC-3=), primer GAPDH A (5=-GAAGATGGTGATGGGATTTC-3=), and a GAPDH
probe (5=-LC640-CAAGCTTCCCGTTCTCAGCCT-BHQ-1) (where LC40 is LightCycler 640 [Roche Diagnostics]
and BHQ-2 is black hole quencher 2). The amount of viral RNA relative to that in the control sample
(DMSO-treated cells) was calculated using the ΔΔCT threshold cycle (CT) method with GAPDH as an
internal control (41). Supernatants were used to inoculate naive Huh7-Lunet-N-hCD81-FLuc cells that had
been seeded the day before at 5  104 cells per well in 12-well dishes. The cells were lysed at 72 h p.i.
in 150 l passive lysis buffer (Promega) per well for the assessment of the Renilla luciferase activity
(infectivity).
Pestivirus replication and infectivity. Cells were lysed at 48 h p.i., and intracellular RNA was
extracted using a NucleoMag 96 RNA kit (Macherey-Nagel, Oensingen, Switzerland) on a Kingﬁsher Flex
system according to the manufacturer’s recommendation. qRT-PCR was performed as described previ-
ously (42) using a QuantiTect probe RT-PCR kit (Qiagen, Hombrechtikon, Switzerland) according to the
manufacturer’s recommendations, and ampliﬁcation was detected using a TaqMan 7500 real-time PCR
system (Applied Biosystems, Thermo Fisher Scientiﬁc). The amount of viral RNA relative to that in the
control sample (DMSO-treated cells) was calculated using the ΔΔCT method with GAPDH as the internal
control (41). Viral titers were determined by serial dilution on BT cells and incubation at 37°C in 5% CO2
for 4 days. BVDV SuwaCp titers were determined by microscopy upon quantiﬁcation of the cytopathic
effect (CPE). BVDV SuwaNcp titers were determined upon ﬁxation, followed by immunoperoxidase (IPO)
staining as described previously (37) using an AEC staining kit (catalog number AEC101-1KT; Sigma-
Aldrich), and viral titers were calculated and expressed as the number of TCID50 per milliliter using the
Spearman-Kärber method.
Cell toxicity and proliferation assays. To evaluate the effect of K22 on cell viability, proliferation,
as well as cytotoxicity, uninfected cells were treated with the compound at the concentrations speciﬁed
above or with DMSO as a control. To determine the effect of K22 on cell viability, Vero cells were
collected and labeled with the Fixable Aqua dead cell stain kit (Thermo Fisher Scientiﬁc) for 30 min on
ice, before the cells were washed with cold PBS and ﬁxed for ﬂow cytometry analysis. As a positive
control for cell death, cells were heated at 65°C for 30 min. The mean ﬂuorescence intensity (MFI) was
determined by ﬂow cytometry analysis on a FACSCanto II ﬂow cytometer (BD Bioscience) and evaluated
using FlowJo (v.9.1) software. To determine the cytotoxicity of K22, the CytoTox 96 nonradioactive
cytotoxicity assay (catalog number G1780; Promega) was used according to the manufacturer’s recom-
mendations. To this end, 1  104 Vero B4 cells (kindly provided by M. Müller, University of Bonn Medical
Centre, Bonn, Germany) or BT cells were seeded in a 96-well format. The compound was added at the
concentrations indicated above, and cytotoxicity was determined at 24 and/or 48 h p.i. by determination
of the absorbance at 490 nm using a plate reader (VersaMax [Molecular Devices, Wokingham, UK] or an
EnSpire 2300 multilabel reader [PerkinElmer, Schwerzenbach, Switzerland]). Cell proliferation following
compound treatment was determined using a MultiTox-Fluor multiplex cytotoxicity assay (catalog
number G9200; Promega) according to the manufacturer’s recommendations. The readout was per-
formed using a multilabel reader (EnSpire 2300 multilabel reader; PerkinElmer) upon excitation at 400
nm and emission at 505 nm. To measure the effects on Huh7-Lunet-N-hCD81-FLuc cell viability, an
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay was per-
formed at 48 h posttreatment. Brieﬂy, an MTT stock solution was prepared by dissolving the compound
(catalog number M5655; Sigma) at 5 mg/ml in PBS, and the stock was diluted 10 times in prewarmed
complete DMEM. The cell supernatant was replaced by the diluted MTT solution (50 l/well), and the
cells were incubated for 1 h at 37°C. The cell supernatant was removed and replaced by 50 l/well DMSO
to dissolve the precipitate, and the absorbance was read at 570 nm.
Time-of-addition assay. To study the effect of K22 on early virus-cell interaction, 8  104 Vero B4
cells were seeded in 12-well plates in DMEM (Gibco) supplemented with 10% (vol/vol) FBS, 1% (vol/vol)
NEA (Gibco), and 1% (vol/vol) penicillin-streptomycin (Invitrogen) and allowed to reach 80% conﬂuence
overnight. Subsequently, K22 at various concentrations was added at speciﬁc time points relative to the
time of infection with ZIKV, and the cell culture supernatants were collected at 24 h p.i. for measurement
of virus release. Shortly, the compound was diluted in DMSO to reach the desired concentrations (0, 5,
10, 20, 30, and 40 M) and incubated with the cells for 2 h prior to infection, during infection, or after
a period of 2, 6, 10, 14, 18, 22, or 24 h. The infection with ZIKV was conducted as follows: cell culture
medium was removed and replaced by 1 ml of DMEM containing ZIKV diluted to an MOI of 0.1
TCID50/cell, and the cells were incubated for 1 h at 37°C in 5% CO2. Next, the inoculum was discarded,
the cells were washed with prewarmed PBS, and culture medium was added to the wells. Additionally,
in order to analyze the direct effect of K22 on virus stability, ZIKV in DMEM was incubated for 2 h at room
temperature with the different K22 concentrations and titrated in 10-fold serial dilution on Vero cells for
measurement of virus infectivity as described above.
Combination treatment. To evaluate the effects of the combination treatment regimens on ZIKV
infectivity, 4 104 Vero B4 cells were seeded in 24-well plates in DMEM (Gibco) supplemented with 10%
(vol/vol) FBS, 1% (vol/vol) NEA (Gibco), and 1% (vol/vol) penicillin-streptomycin (Invitrogen) and allowed
to reach 80% conﬂuence overnight. The cells were infected with ZIKV at an MOI of 0.1 TCID50/cell at 37°C
in 5% CO2 for 1 h, before the inoculum was discarded and the cells were washed with prewarmed PBS.
Compounds were added at various concentrations (for K22 diluted in DMSO, 0, 5, 10, 20, 30, or 40 M;
for RBV diluted in H2O, 0.1, 1, 10, 100, and 1,000 g/ml; for IFN- diluted in H2O, 1, 10, 100, or 1,000
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IU/500 l) either as single agents or in combination. The cell culture supernatants were collected at 24
h p.i., and the viral titers were determined using the IPMA as described above and calculated as the
number of TCID50 per milliliter. Cell proliferation upon combination treatment was determined using the
MultiTox-Fluor multiplex cytotoxicity assay (Promega) as described above.
Immunoﬂuorescence analysis. Vero cells were seeded on 8-chamber Lab-Tek II slides (Nunc; Milian,
Geneva, Switzerland) and pretreated with 30 M K22 or DMSO for 4 h. Cells were infected with ZIKV, JEV,
and WNV at an MOI of 0.1 TCID50/cell in medium supplemented with 30 M K22 or equivalent volumes
of DMSO as a control. Cells were washed with PBS at 1 h p.i. and incubated in medium supplemented
with 30 M K22 or equivalent volumes of DMSO for an additional 48 h. Cells were ﬁxed with 4% (wt/vol)
PFA, permeabilized, and blocked with a PBS solution supplemented with 1% (vol/vol) FBS and 0.3%
(wt/vol) saponin. E protein and dsRNA replication intermediates were detected using anti-ﬂavivirus group
antigen antibody (1:10; catalog number HB-112; ATCC) and anti-dsRNA J2 MAb (1:200; English and
Scientiﬁc Consulting). Alexa Fluor 488-coupled anti-mouse IgG2a antibodies were used as secondary
antibodies. Alexa Fluor 633-coupled phalloidin (Invitrogen) and DAPI (4=,6-diamidino-2-phenylindole)
were used to counterstain the actin cytoskeleton and nuclei, respectively. Slides were mounted in Mowiol
mounting medium. For microscopy analysis, a Nikon confocal A1 microscope (Nikon AG, Egg, Switzer-
land) combined with an Eclipse Ti inverted microscope (Nikon) and digital imaging Nikon software
(NIS-Elements AR, v.3.30.02) were used. Image acquisitions were performed in stacks of 0.2 m over at
least a 10-m thickness using a 40 objective, and sequential and not simultaneous channel acquisition
was employed; in order to give high-resolution images, the acquisition setting was performed with an
optimized voxel size and an automatic threshold. The images were analyzed with Imaris (v.8.0.2) software
(Bitplane AG, Zurich, Switzerland). To avoid false-positive emissions, different settings, including those for
background subtraction, threshold applications, gamma correction, and maxima, were applied.
Transmission electron microscopy. Vero B4 cells were seeded in 24-well plates and pretreated with
30 M K22 or DMSO for 2 h. Cells were infected with ZIKV (MOI  10 TCID50/cell) in medium
supplemented with 30 M K22 or equivalent volumes of DMSO. Cells were washed with PBS at 1 h p.i.
and incubated in medium supplemented with 30 M K22 or equivalent volumes of DMSO. Processing
of samples for TEM was performed as described by Schätz et al. (43). Shortly, cells were ﬁxed at 24 h p.i.
with 2.5% (wt/vol) glutaraldehyde (Merck, Darmstadt, Germany) in 0.1 M cacodylate buffer (Merck,
Hohenbrunn, Germany), pH 7.4, and postﬁxed with 1% (wt/vol) OsO4 (Chemie Brunschwig, Basel,
Switzerland) in 0.1 M cacodylate buffer. Thereafter, cells were dehydrated in an ascending ethanol series
(70%, 80%, 90%, 94%, 100%, 100%, 100% [vol/vol] for 20 min each) and embedded in Epon resin, which
is a mixture of Epoxy embedding medium, dodecenyl succinic anhydride (DDSA), and methyl nadic
anhydride (MNA) (Sigma-Aldrich, Buchs, Switzerland). Ultrathin sections of 90 nm were then obtained
with diamond knives (Diatome, Biel, Switzerland) on a Reichert-Jung Ultracut E microtome (Leica,
Heerbrugg, Switzerland) and collected on collodion-coated 200-mesh copper grids (Electron Microscopy
Sciences, Hatﬁeld, PA, USA). Sections were double stained with 0.5% (wt/vol) uranyl acetate for 30 min
at 40°C (Sigma-Aldrich, Steinheim, Germany) and 3% (wt/vol) lead citrate for 10 min at 20°C (Laurylab,
Saint Fons, France) in Ultrastain (Leica, Vienna, Austria) and examined with a Philips CM12 TEM (FEI,
Eindhoven, The Netherlands) at an acceleration voltage of 80 kV. Micrographs were captured with a
Mega View III camera using iTEM software (v.5.2; Olympus Soft Imaging Solutions GmbH, Münster,
Germany).
Statistical evaluation. Testing of the statistical signiﬁcance of the differences in the mean values
was performed using GraphPad Prism (v.7.04) software for Windows (GraphPad Software, La Jolla, CA,
USA). Either one-way or two-way analysis of variance (ANOVA) was used, followed by Dunnett’s
multiple-comparison testing. IC50s and IC90s were calculated from nonlinear regression analyses with the
least-squares ﬁt method, and the upper and lower plateaus were set to 100 and 0, respectively.
Signiﬁcant outliers were removed after performing Grubbs’ test (QuickCalcs; GraphPad). Drug combina-
tion analysis was performed using CompuSyn, a computer program for quantitation of the synergism
and antagonism of drug combinations (44).
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